Recent Updates
Recently added Catalysts
UTHR Positive Sentiment

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026

Key Takeaway: United Therapeutics Corporation will report its fourth quarter and full year 2025 financial results on February 25, 2026. A press release will be issued at 6:30 a.m. ET, followed by a public webcast at 9:00 a.m. ET. The company emphasizes its commitment to innovation and social responsibility as a public benefit corporation.
Price reaction · baseline $473.2 (2026-02-10 close) · hit pre-market · clean, no other UTHR news in the window
day 0 close · peak
+0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • United Therapeutics is committed to addressing unmet medical needs.
  • The company is innovative in developing novel pharmaceutical therapies.
  • They are a public benefit corporation, emphasizing social responsibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+21%
120-day peak, hindsight
Typical move
10.8%
average across 6 past catalysts
Lead asset
UBT251
Phase 2 · Obesity &Amp; Overweight

Full Press Release Details

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq:UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.
United Therapeutics will host a public webcast Wednesday, February 25, 2026, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics’ website athttps://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location.

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
You can learn more about what it means to be a PBC here:unither.com/pbc.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February 11, 2026, and assume no obligation to update or revise the information contained in this press release whether because of new information, future events or any other reason.

Frequently Asked Questions

When will United Therapeutics report its financial results?

United Therapeutics will report its financial results on February 25, 2026.

What time is the webcast for the financial results?

The webcast will take place at 9:00 a.m. Eastern Time.

Where can I access the webcast?

The webcast can be accessed via United Therapeutics' website.

What is the purpose of United Therapeutics as a PBC?

United Therapeutics aims to develop novel therapies and expand transplantable organ availability.

Last updated: Feb 11, 2026